Kura Oncology, Inc.
KURA
$9.22
-$0.52-5.34%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -61.95% | -60.17% | -9.79% | -8.49% | -8.21% |
| Total Depreciation and Amortization | 34.04% | 21.70% | -2.91% | 1.27% | -2.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.13% | 36.92% | 25.08% | 8.00% | 10.35% |
| Change in Net Operating Assets | -32.11% | -35.55% | 3,557.26% | 4,237.40% | 2,563.24% |
| Cash from Operations | -170.11% | -147.69% | 151.92% | 180.79% | 180.72% |
| Capital Expenditure | -852.06% | -1,306.36% | -3,942.24% | -1,460.29% | -214.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 165.95% | 93.61% | -208.67% | -6,912.97% | -17.96% |
| Cash from Investing | 159.52% | 87.11% | -222.21% | -6,389.27% | -18.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -72.23% | -98.84% | -99.05% | -97.59% | -97.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -72.23% | -98.84% | -99.05% | -97.59% | -97.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -224.82% | -140.27% | 120.86% | 1,032.89% | -32.42% |